SCM
WHWK

Stonepine Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Stonepine Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,253
Closed -$67K – 89
2025
Q3 		$67K Buy
+35,253
New +$64.8K 0.05% 57
2025
Q2 		– Sell
-46,698
Closed -$83.1K – 87
2025
Q1 		$83.1K Buy
+46,698
New +$122K 0.08% 58

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Stonepine Capital Management's WHWK Position: Q4 2025 in Review

Stonepine Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q4 2025, closing a stake of 35,253 shares — an estimated $67K sold.

Stonepine Capital Management first reported a position in WHWK in Q1 2025 and held it in 2 quarters. The position peaked at $83.1K in Q1 2025. 48 funds tracked by Wall St. Rank hold WHWK as of Q4 2025.

  • Stonepine Capital Management reported no remaining Whitehawk Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 35,253 Whitehawk Therapeutics shares in Q4 2025, an estimated $67K.
  • Stonepine Capital Management first reported a position in Whitehawk Therapeutics in Q1 2025 and held it in 2 quarters.
  • Stonepine Capital Management's Whitehawk Therapeutics position peaked at $83.1K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.